U.S. markets close in 3 hours 54 minutes

Zimmer Biomet Holdings, Inc. (ZBH)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
166.52-0.75 (-0.45%)
As of 12:06PM EDT. Market open.
Sign in to post a message.
  • L
    Lynton
    Some credit due for the spin the company executives put on a soft quarter. The inability to make meaningful debt reduction is a lingering concern. The company may not financially positioned to combat the never ending litigation processes (lawsuits, recalls, product liability issues) that regularly occurs in this type of business. The debt seems to be manageable, but only if the business dynamics remain positive. High profit core implant growth patterns are concerning. Leary that the new technology platforms being highlighted can add meaningful dollars to the bottom line. Nice technologies to talk about, but time will tell if they play out. Undoubtedly, the current political health care climate will reinstate pricing pressures going forward. Every quarter the company boasts how good their management team is, a little less bragging and a little more growth/profitability would be reassuring. The stock price is favorable because of the overall market, if the market begins to pull back, the price will pull back quickly without some real sales growth. Is the risk greater than the rewards?
  • s
    sisti
    $$ The 7 Best Food Stocks To Buy Right Now$$ . For more info https://youtu.be/VmSfWN5U1dw
    Food is the fuel to our chemical engines and without it we’d be… well… stuffed. Although consumers may visit restaurants less during tough economic times, th...
    Food is the fuel to our chemical engines and without it we’d be… well… stuffed. Although consumers may visit restaurants less during tough economic times, th...
    www.youtube.com
  • W
    Warren
    ✅CNBC. Entertaining this and ASXC @ $3.01 is the one they should be talking about more. TEN times upside and ISRG @ $710 is its closest competitor
    Bullish
  • L
    Lynton
    Increasing the debt, renewed going forward pricing pressures, and the spin off of Dental and Spine (spinning off more than likely means they couldn't find a buyer, not marketable segments) makes the outlook in question. Agree it has been a tough year, but leadership doesn't seem to be reacting accordingly.
  • S
    StockStuffer
    $ASYS conversation
    The robotic surgery market includes
    $MDT market cap 158B
    $ISRG market cap 94B
    $SYK market cap 91B
    $ZBH market cap 34B
    $EDAP
    A lesser known play that uses high frequency ultrasound to target cancer without the incision is EDAP if you want to broaden the portfolio. The robotics guides the waves and essentially burns the cancer cells killing them and the body takes care of the rest.
  • D
    DueDiligenceSmart
    AcelRx Pharmaceuticals, Inc.
    $PFE $MRK or $ZBH bidding war for ACRX... ACRX jumped 10% on Volume... news leak!
    Bullish
  • T
    The Batman
    50% drop in 1 month?! I used to own this stock. Anyone care to comment on what has happened (other than the obvious Covid stuff)?
  • a
    annie
    Does anyone have an opinion on the earnings tmrw.?
  • T
    The Batman
    Great results followed by immediate large drop. The norm on wall st it seems.
  • A
    Anonymous
    What happens in 2021 when Lorecicivant comes to market?

    https://www.fiercebiotech.com/biotech/conversation-osman-kibar-ceo-samumed

    SNIP:
    Take Samumed’s lead program, lorecivivint, which is in phase 3 for knee osteoarthritis. There is no treatment for osteoarthritis that reverses damage to the joint, so doctors focus on managing symptoms: They prescribe exercise and weight loss to improve muscle strength and reduce burden on joints as well as drugs such as painkillers, anti-inflammatory meds and cortisone injections. Some patients may eventually undergo joint repair or replacement surgery.

    Lorecivivint is designed to fix joint damage, so patients don’t need to go through all that.

    Samumed expects its phase 3 osteoarthritis study to read out by the end of 2020 and hopes to submit lorecivivint for FDA approval in the first quarter of 2021.
    Samumed CEO Osman Kibar discusses regenerative medicine, drugging the Wnt pathway and his company's unorthodox journey.
    Samumed CEO Osman Kibar discusses regenerative medicine, drugging the Wnt pathway and his company's unorthodox journey.
    www.fiercebiotech.com
  • s
    stocktargetadvisor
    $ZBH
    Target Raised by BTIG Research Buy USD 160 » USD 173
  • r
    roy
    Strong Buy Recommendation by Needham, according to Barron's today. Target increased to $185.
  • S
    Steve
    gunna be honest, u would be lucky to find a green stock in this market. lucky this wasnt hit too hard.
  • Y
    Yahoo Finance Insights
    ZBH reached an all time high at 138.09
  • L
    Lynton
    Selling debt to pay debt, not a good sign
  • L
    Lauren
    Looks pretty positive.
  • J
    Jon
    Will Zimmer buy ACRX?
  • a
    alejandro
    If i where you reading this id sell as fast as you can , this is going to drop without any news and in addition watch the trends going on !!!!! SELL SELL SELL!!!!
  • M
    Michael
    Earnings per share grew at a rate of 41% year over year. A very good sign. I have two of their hips and absolutely love em! ZBH will continue to grow ,for years to come with the many patents they hold.
    Bullish
  • c
    claudio
    Wow it kept some of its upside